Shield Therapeutics plc
SHIEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $32,180 | $13,085 | $4,549 | $1,519 |
| % Growth | 145.9% | 187.7% | 199.5% | – |
| Cost of Goods Sold | $17,250 | $9,058 | $2,516 | $980 |
| Gross Profit | $14,930 | $4,027 | $2,033 | $539 |
| % Margin | 46.4% | 30.8% | 44.7% | 35.5% |
| R&D Expenses | $1,887 | $1,973 | $1,320 | $579 |
| G&A Expenses | $10,759 | $15,172 | $11,023 | $20,023 |
| SG&A Expenses | $34,588 | $36,889 | $30,773 | $20,150 |
| Sales & Mktg Exp. | $23,829 | $21,717 | $19,750 | $13,994 |
| Other Operating Expenses | $1,328 | -$3,504 | $11,096 | $104 |
| Operating Expenses | $37,803 | $35,358 | $43,189 | $20,833 |
| Operating Income | -$22,873 | -$31,331 | -$41,156 | -$20,294 |
| % Margin | -71.1% | -239.4% | -904.7% | -1,336% |
| Other Income/Exp. Net | -$3,683 | -$1,044 | $338 | $387 |
| Pre-Tax Income | -$26,556 | -$32,375 | -$40,818 | -$19,907 |
| Tax Expense | $626 | $918 | $369 | -$229 |
| Net Income | -$27,182 | -$33,293 | -$49,789 | -$19,678 |
| % Margin | -84.5% | -254.4% | -1,094.5% | -1,295.5% |
| EPS | -0.03 | -0.046 | -0.21 | -0.092 |
| % Growth | 34.9% | 78% | -128.5% | – |
| EPS Diluted | -0.03 | -0.046 | -0.21 | -0.092 |
| Weighted Avg Shares Out | 906,067 | 722,544 | 237,906 | 210,421 |
| Weighted Avg Shares Out Dil | 906,067 | 722,544 | 237,906 | 210,421 |
| Supplemental Information | – | – | – | – |
| Interest Income | $266 | $518 | $36 | $18 |
| Interest Expense | $3,873 | $1,016 | $404 | $11 |
| Depreciation & Amortization | $1,425 | $1,071 | $1,631 | $1,541 |
| EBITDA | -$21,258 | -$30,288 | -$24,547 | -$18,753 |
| % Margin | -66.1% | -231.5% | -539.6% | -1,234.6% |